Our study suggests that these additional extra-hepatic benefits of DPP-4 inhibitors are potentially important, not only in NAFLD, but also for T2DM patients with chronic hepatitis virus infection. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.